The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.

source https://finance.yahoo.com/news/allergans-filings-abicipar-pegol-accepted-100110182.html?.tsrc=rss